Reported Earlier, Eisai And Submit LEQEMBI BLA For Subcutaneous Alzheimer's Treatment To FDA, Targeting Early Disease Stages
Portfolio Pulse from Benzinga Newsdesk
Eisai and Biogen have submitted a Biologics License Application (BLA) to the FDA for a subcutaneous version of LEQEMBI, targeting early-stage Alzheimer's. The application is based on data from the Clarity AD study. If approved, the LEQEMBI autoinjector could be used at home or in medical facilities, offering a more convenient administration method.
November 01, 2024 | 7:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biogen, in collaboration with Eisai, has submitted a BLA for a subcutaneous version of LEQEMBI to the FDA. This could lead to a new, more convenient treatment option for early-stage Alzheimer's patients.
The submission of the BLA for a subcutaneous version of LEQEMBI represents a significant development for Biogen, as it could lead to a new product offering in the Alzheimer's treatment market. This could positively impact Biogen's stock if approved, due to the potential for increased market share and convenience for patients.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80